Translatome Remodeling by Fasting Regulates Tumorigenesis via eIF4E

Study Background and Research Question

Fasting and ketogenic diets have long been associated with broad health benefits, such as weight loss, neuroprotection, and reduced cancer risk. These effects are mediated by metabolic rewiring, particularly the shift from glucose to ketone bodies as the primary energy source. However, the molecular mechanisms by which fasting and dietary interventions reshape cellular proteomes and influence cancer metabolism have remained unresolved. The reference study (Yang et al., Nature 2024) addresses a critical question: how does fasting regulate selective protein synthesis in the liver, and how does this process impact tumorigenesis?

Key Innovation from the Reference Study

The central innovation of Yang et al. lies in identifying a previously uncharacterized translational control mechanism during fasting. Contrary to the expectation that global translation is uniformly suppressed under nutrient deprivation, the authors demonstrate that hepatocytes remodel their translatome through selective phosphorylation of eukaryotic translation initiation factor 4E (eIF4E). This post-translational modification enables the translation of a specific subset of mRNAs crucial for lipid catabolism and ketogenesis, while overall protein synthesis remains downregulated. Mechanistically, the study uncovers a lipid-mediated signaling pathway—wherein fasting-induced fatty acids activate AMP-activated protein kinase (AMPK), which in turn phosphorylates mitogen-activated protein kinase-interacting kinase (MNK), culminating in eIF4E phosphorylation. This AMPK-MNK-eIF4E axis integrates dietary cues with translational reprogramming, establishing ketogenesis as a selective, actively regulated process at the level of mRNA translation. Importantly, the study links this axis to tumor metabolism, showing that inhibition of eIF4E phosphorylation can restrain pancreatic tumor growth in the setting of a ketogenic diet.

Methods and Experimental Design Insights

The investigators utilized a combination of in vivo mouse models, metabolic assays, and translatome profiling to dissect the fasting response. Mice were subjected to fasting or ketogenic diet regimens, and liver tissues were analyzed for translational activity using ribosome profiling (Ribo-seq) and polysome fractionation. Phosphorylation states of eIF4E and upstream kinases were assessed by immunoblotting and phospho-specific antibodies. Selective translation of lipid catabolism and ketogenesis-related mRNAs was validated by quantitative RT-PCR and reporter assays, focusing on 5’ untranslated region (5’UTR) regulatory elements. The signaling function of fatty acids was tested by direct FA supplementation and kinase activity assays. To probe the role in tumor biology, pancreatic cancer models were treated with a clinical eIF4E phosphorylation inhibitor (eFT508) in the context of ketogenic diet.

Core Findings and Why They Matter

• Selective Translatome Remodeling: Fasting or ketogenic diet decreased overall liver protein synthesis, as expected, yet specifically enhanced the translation of genes involved in lipid oxidation and ketone body production. This selective translation was mediated by increased phosphorylation of eIF4E.
• Fatty Acid-Driven Signaling: Long-chain fatty acids, elevated during fasting, were shown to act as direct signaling molecules, activating AMPK. This nutrient-sensing pathway then stimulates MNK, the kinase responsible for eIF4E phosphorylation.
• Translational Regulatory Elements: The mRNAs selectively translated during fasting harbor unique 5’UTR elements that render them responsive to P-eIF4E, revealing a layer of specificity in diet-induced translational control.
• Cancer Metabolism Implications: Certain tumors, such as pancreatic cancer, exploit ketone bodies as an energy substrate. The study demonstrated that blocking eIF4E phosphorylation with eFT508 curtails pancreatic tumor growth in mice fed a ketogenic diet, indicating that this translational control mechanism represents a metabolic vulnerability in cancer (Yang et al.).

Together, these findings reveal that the physiological adaptation to fasting is not merely a passive shutdown of protein synthesis but involves an active, signal-driven reprogramming of translation. The AMPK-MNK-eIF4E axis serves as a molecular bridge between dietary input and the selective expression of metabolic genes, with direct relevance for understanding and targeting cancer metabolic plasticity.

Comparison with Existing Internal Articles

While the reference paper investigates translational remodeling via eIF4E in response to dietary cues, recent internal reviews, such as "ZK53: Redefining Human ClpP Activation for Cancer Mitochondrial Research" and "ZK53 and Human ClpP: Mechanistic Insights for Advanced Oncology Models", focus on the pharmacological activation of mitochondrial proteases as a complementary avenue for disrupting tumor metabolism. For instance, ZK53, a highly selective human mitochondrial serine protease ClpP activator, has been shown to induce mitochondrial dysfunction, oxidative phosphorylation inhibition, and cell cycle arrest in cancer cells. These effects, detailed in "Selective Human ClpP Activation Induces Cell Cycle Arrest in LUSC", mirror several downstream consequences of translational reprogramming described in the reference study—such as impaired mitochondrial metabolism and induction of cell death pathways.

Moreover, both lines of research illuminate distinct but convergent strategies for targeting tumor metabolic adaptability: one via control of mRNA translation in response to dietary signals, the other via direct pharmacological disruption of mitochondrial proteostasis. When viewed together, these approaches highlight the interconnectedness of nutrient sensing, mitochondrial function, and translational control in cancer biology.

Limitations and Transferability

The study by Yang et al. provides compelling mechanistic insights, but several limitations should be noted. First, the principal findings are derived from liver tissue; the extent to which similar translatome remodeling occurs in other tissues or in different tumor types requires further investigation. The in vivo cancer model focused on pancreatic tumors, which are known to utilize ketone bodies—thus, generalizability to cancers with distinct metabolic profiles remains to be established. Additionally, while the AMPK-MNK-eIF4E axis was shown to be necessary for fasting-induced selective translation, the pharmacological inhibition of this pathway (e.g., using eFT508) in cancer therapy warrants further validation in diverse preclinical and clinical settings.

Importantly, the transferability of these findings to human dietary interventions or combination therapies with mitochondrial-targeting agents should be approached cautiously. Metabolic adaptation in humans is subject to inter-individual variability, and the clinical efficacy and safety of manipulating such central signaling nodes require rigorous study.

Research Support Resources

To support experimental interrogation of mitochondrial proteostasis and metabolic vulnerability in cancer, researchers may consider the use of ZK53 (SKU BA8004), a highly selective human mitochondrial serine protease ClpP activator. According to the product information, ZK53 induces mitochondrial electron transport chain disruption and oxidative phosphorylation inhibition, which can be leveraged in workflows examining the intersection of translational control, mitochondrial function, and cancer metabolism. ZK53 has been validated in both in vitro and in vivo cancer models, including lung squamous cell carcinoma and colorectal cancer xenografts.

Protocol Parameters

• In vitro concentrations: 10 μM for HT-1080 cells, 1 μM for HeLa cells, 5 μM for HCT-116 cells are typical non-toxic working concentrations.
• In vivo dosing regimens: For lung squamous cell carcinoma xenograft models, 80 mg/kg intraperitoneally twice daily; for colorectal cancer models, 20 mg/kg every other day in combination with ferroptosis inducers.
• Stability: Solid form should be stored at −20°C; solutions for short-term use only.

These resources, along with insights from the referenced study, provide a robust platform for dissecting how metabolic and translational interventions can be applied to cancer research. For further mechanistic and protocol guidance, researchers can consult the internal reviews linked above.